IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3147
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$8.8B
Joseph K. Belanoff
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the. treatment of hyperglycemia secondary to hypercortisolism in adult patients with. endogenous Cushing's syndrome.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = CORT ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$CORT CORCEPT THERAPEUTICS INC | 43 | 68 | 55 | 12 | 29.9x | 42.1x | 19.4% | 14.9% | 98.2% | 11.6% | 16.6% | 26.8% | 0.0% | 30.0x | $8.8B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
CORCEPT THERAPEUTICS INC (CORT) receives a "Reduce" rating with a composite score of 42.8/100. It ranks #3147 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Joseph K. Belanoff
Chief Executive Officer
Labor Force
300
68
42
24
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for CORT
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for CORT.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy 19.4% (sector -2.5%)
GM 98% vs sector 43%, OM 12% vs sector 1%
Capital turnover N/A, R&D intensity 34.0%
Rev growth 27%, 10yr history
Interest coverage N/A, Net debt/EBITDA -12.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
CORCEPT THERAPEUTICS INC receives a Reduce rating from our analysis, with a composite score of 42.8/100 and 2 out of 5 stars, ranking #3147 out of 7,333 stocks. CORT's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
CORT earns a quality score of 68/100, indicating above-average business quality. The company reports a return on equity of 19.4% (sector avg: -2.5%), gross margins of 98.2% (sector avg: 42.5%), net margins of 16.6% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
CORT's value score of 55/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 29.88x, an EV/EBITDA of 42.14x, a P/B ratio of 5.80x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
With an investment score of 42/100, CORT exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 26.8% vs. a sector average of 5.9% and a return on assets of 14.9% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
CORCEPT THERAPEUTICS INC is experiencing notably weak momentum with a score of just 12/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 26.8% year-over-year, while a beta of 1.29 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
CORCEPT THERAPEUTICS INC registers a low stability score of 24/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.29 and a debt-to-equity ratio of 30.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
CORCEPT THERAPEUTICS INC's short interest score of 38/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.29), elevated leverage (D/E: 30.00x). At $8.8B (mid-cap), CORT carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
CORCEPT THERAPEUTICS INC is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3147 of 7,333 overall (57th percentile). Key comparisons include ROE of 19.4% exceeding the -2.5% sector median and operating margins of 11.6% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CORT currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (12) would have the largest impact on the composite score.
EV/EBITDA 268% ABOVE SECTOR MEDIAN
ROE 882% BELOW SECTOR MEDIAN
Gross Margin 131% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate CORCEPT THERAPEUTICS INC (CORT) as a Reduce with a composite score of 42.8/100 at a current price of $34.81. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in quality (68th percentile) and value (55th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (12th percentile) and stability (24th percentile) tempers our overall conviction. We assign a Narrow Moat rating (65/100), High uncertainty, and Standard capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
CORCEPT THERAPEUTICS INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 42.8/100 places it at rank #3147 in our full 7,333-stock universe. At $8.8B in market capitalization, CORCEPT THERAPEUTICS INC is a mid-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 27%, though momentum at the 12th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 98% (+55.7pp vs sector) narrow to operating margins of 12% (+10.3pp vs sector) and net margins of 16.6%, yielding a gross-to-net conversion rate of 17%. This conversion rate is typical for the sector, suggesting a standard cost structure without notable efficiency advantages or disadvantages.
At a current price of $34.81, CORCEPT THERAPEUTICS INC is trading near fair value based on current fundamentals. Our value factor score of 55/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 29.9x (a 34% premium to the sector median of 22.3x), EV/EBITDA of 42.1x (at a premium), P/B of 5.8x, P/S of 4.9x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis partially supports given strong quality metrics.
Gross margins of 98% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 19.4% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 27% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Return on assets of 14.9% indicates efficient deployment of the full asset base, not just equity capital.
The Reduce rating (composite 42.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
We assign a High uncertainty rating to CORCEPT THERAPEUTICS INC. Key risk factors include below-average price stability (24th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: below-average price stability (24th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 24th percentile and quality factor at the 68th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 98% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate CORCEPT THERAPEUTICS INC's capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 19.4%, and the balance sheet is managed within acceptable parameters (D/E: 30%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; CORCEPT THERAPEUTICS INC falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, CORCEPT THERAPEUTICS INC receives a Reduce rating with a composite score of 42.8/100 (rank #3147 of 7,333). Our quantitative framework assigns a Narrow Moat (65/100, trend: stable), High uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 40/100.
Our analysis does not support a constructive view on CORCEPT THERAPEUTICS INC at this time. The combination of the current quantitative profile, high uncertainty, and standard capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign CORCEPT THERAPEUTICS INC a Narrow Moat rating with a composite moat score of 65/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that CORCEPT THERAPEUTICS INC can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being growth durability at 19.3/20.
The strongest moat sources are growth durability (19.3/20) and margin superiority (18.4/20). Rev growth 27%, 10yr history. GM 98% vs sector 43%, OM 12% vs sector 1%. These pillars form the core of CORCEPT THERAPEUTICS INC's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (7/20) and economic value creation (9.4/20). Capital turnover N/A, R&D intensity 34.0%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect CORCEPT THERAPEUTICS INC's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 98% providing a solid profitability foundation, operating margins of 12% reflecting effective cost management, robust top-line growth of 27% expanding the revenue base. The margin cascade from 98% gross to 12% operating to 16.6% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 68th percentile.
The margin profile shows gross margins of 98%, operating margins of 12%, net margins of 16.6%. Return metrics include ROE of 19.4% and ROA of 14.9%. Relative to the Manufacturing sector, gross margins are 55.7 percentage points above the sector median of 43%, and ROE of 19.4% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 30%, revenue growth of 27%. The sector median D/E is 0%, putting CORCEPT THERAPEUTICS INC at higher leverage than the typical peer. The combination of low leverage and healthy profitability provides significant financial resilience and strategic optionality.
Weak momentum (12th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Above 50MA
37.18%
Net New Highs
+51081
REDWOOD CITY, Calif., February 24, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025.
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 11.1% year on year to $202.1 million. Its GAAP profit of $0.20 per share was 26.3% below analysts’ consensus estimates.